Apr 18, 2024
Immutep Appoints Leading Research Institute to Conduct First-in-Human Phase I Study of IMP761
Apr 17, 2024
Immutep Receives Positive Feedback from the Spanish Medicines Agency for Upcoming TACTI-004 Registrational Trial in Metastatic Non-Small Cell Lung Cancer
Mar 05, 2024
Immutep Announces First Clinical Data from 90mg Dosing of Efti
Jan 30, 2024
Immutep Quarterly Activities Report Q2 FY24
Jan 04, 2024
First Patient Dosed in Trial Evaluating Efti and the Anti-PD-L1 Therapy BAVENCIO® in Metastatic Urothelial Cancer
Dec 20, 2023
Immutep Receives Constructive Regulatory Feedback on TACTI-004 Registrational Trial in Metastatic Non-Small Cell Lung Cancer
Dec 07, 2023
Immutep Receives A$2.6 million R&D Tax Incentive from French Government
Nov 22, 2023
Immutep Announces Site Expansion for INSIGHT-003 Phase I Trial
Nov 09, 2023
Immutep Completes Enrollment in TACTI-003 Phase IIb Trial of Efti and KEYTRUDA® in First Line Metastatic or Recurrent Head and Neck Squamous Cell Carcinoma
Nov 06, 2023
Immutep Announces Completion of the Safety Lead-In and Opening of the Randomized Phase II of the AIPAC-003 Phase II/III Trial in Metastatic Breast Cancer
Nov 02, 2023
Immutep Announces New Biomarker Data from TACTI-002 Phase II in First Line Non-Small Cell Lung Cancer
Nov 01, 2023
Immutep to Participate in November Investor Events
Oct 30, 2023
Immutep Quarterly Activities Report Q1 FY24
Oct 25, 2023
Immutep Receives ~A$1.13 Million R&D Tax Incentive
Oct 24, 2023
Immutep Reports Promising Clinical Data from INSIGHT-003 Trial at ESMO Congress 2023
